Results of observational study to determine K-ras mutation rates in 2458 patients with metastatic colorectal cancer in Turkey (TURKRAS Study).
Bildiriler > Özet Bildiri
Yazarlar: Mahmut Gumus, Faysal Dane, Bulent Karabulut, Kazim Uygun, Kubra Aydin, Bulent Orhan, Berna Oksuzoglu, Oktay Tarhan, Suleyman Buyukberber, Kerem Okutur, Idris Yucel, Nurullah Zengin, Abdurrahman Isikdogan, Tugba Unek, Sinan Yavuz, Hakan Harputluoglu, Ridvan Seckin Ozen, TURKRAS STUDY GROUP
Journal of Clinical Oncology, , , Uluslararası, Özet Bildiri, Wos, cilt 33, ss e14516-e14516
DOI: 10.1200/jco.2015.33.15_suppl.e14516
Özet
e14516 Background: Primarily we aimed to investigate the frequency of K-ras mutation in colorectal cancer patients in Turkey, and secondly to determine the frequency of sub-types of the K-ras mutation and the relationship between demographic characteristics. Methods: Prospective, single-arm, multi-center, non-comparative, case-based, epidemiologic observational study of two years duration. All samples for K-ras examination were evaluated by an accredited, independent central laboratory in Turkey. The laboratory procedures to be performed for pathologic specimens obtained from the patients are sample preparation, DNA isolation, amplification by polymerase chain reaction method and identification of the mutations in codons 12 and 13 of the K-ras gene using minisequencing method. Results: We have planned to enroll 2500 metastatic colorectal cancer patients to the study from 52 centers in Turkey. This is the final analysis with the data obtained from 2458 mCRC patients. 38.8% of patients were female. Majority of the patients (42.5%) were from Marmara region. Patients from other regions were distributed as the Middle Anatolia, Aegean, Mediterranean and Southeastern Anatolia, Black Sea regions; and the percentage of patients included from these regions were 21.6%, 13.2%, 11.9%, and 10.9% respectively. The frequency of K-ras mutations in all patients were 45%. There is significantly high K-ras mutation frequency in female patients. Mutation frequency in female was 48.8% (p = 0.002). G12D and G12V mutations are the common mutations with the mutation rates of 28% and 25.9% respectively. G12V mutation is significantly more frequent in female when compared with male patients (14.8% vs 11.1%, p = 0.007). There is no significant difference between the frequency of G12 and G13 mutations when compared according to regional distribution. (p > 0.05). Conclusions: In our study, the detection rate of KRAS mutation is higher in female mCRC patients than the males. In Turkish population, G12V mutation is significantly more frequent in female patients when compared with male patients. Further prospectively generated detailed investigations are necessary to confirm and define these data.